These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8930442)

  • 1. Prevalence of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation.
    Scheiblauer H; Nübling M; Willkommen H; Löwer J
    Clin Ther; 1996; 18 Suppl B():59-70. PubMed ID: 8930442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.
    Yei S; Yu MW; Tankersley DL
    Transfusion; 1992; 32(9):824-8. PubMed ID: 1335184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sensitive PCR method for detecting HCV RNA in plasma pools, blood products, and single donations.
    Saldanha J; Minor P
    J Med Virol; 1994 May; 43(1):72-6. PubMed ID: 8083652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.
    Louie RE; Galloway CJ; Dumas ML; Wong MF; Mitra G
    Biologicals; 1994 Mar; 22(1):13-9. PubMed ID: 8068309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
    Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
    Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of the gene amplification technique to decrease the risk of hepatitis C virus transmission by plasma products.
    Branović K; Forcis D; Kosutic-Gulija T; Santak M; Zgorelec R; Mazuran R
    J Chromatogr A; 1999 Aug; 852(1):305-12. PubMed ID: 10480255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
    Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
    Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data.
    Yap PL
    Clin Ther; 1996; 18 Suppl B():43-58. PubMed ID: 8930441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective.
    Loubière S; Rotily M; Durand-Zaleski I; Costagliola D
    Vox Sang; 2001 May; 80(4):199-204. PubMed ID: 11438026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The viral safety of intravenous immune globulin.
    Yap PL
    Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous extraction of hepatitis C virus (HCV), hepatitis B virus, and HIV-1 from plasma and detection of HCV RNA by a reverse transcriptase-polymerase chain reaction assay designed for screening pooled units of donated blood.
    Sun R; Schilling W; Jayakar H; Ku J; Wang J; Rosenstraus M; Spadoro J
    Transfusion; 1999 Oct; 39(10):1111-9. PubMed ID: 10532606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
    Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
    Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus.
    Chou ML; Burnouf T; Chang SP; Hung TC; Lin CC; Richardson CD; Lin LT
    PLoS One; 2015; 10(2):e0117800. PubMed ID: 25658612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products.
    Steinmann E; Gravemann U; Friesland M; Doerrbecker J; Müller TH; Pietschmann T; Seltsam A
    Transfusion; 2013 May; 53(5):1010-8. PubMed ID: 22905868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.
    Farcet MR; Lackner C; Antoine G; Rabel PO; Wieser A; Flicker A; Unger U; Modrof J; Kreil TR
    Transfusion; 2016 Feb; 56(2):383-91. PubMed ID: 26399175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection with hepatitis G virus among recipients of plasma products.
    Jarvis LM; Davidson F; Hanley JP; Yap PL; Ludlam CA; Simmonds P
    Lancet; 1996 Nov; 348(9038):1352-5. PubMed ID: 8918279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and characterization of hepatitis C virus RNA in immune globulins.
    Yu MY; Mason BL; Tankersley DL
    Transfusion; 1994 Jul; 34(7):596-602. PubMed ID: 7519795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of bovine viral diarrhoea virus as an internal control in nucleic acid amplification tests for hepatitis C virus RNA in plasma-derived products.
    Yoo SH; Hong SH; Jung SR; Park SJ; Lee NK; Kim SN; Kang SM; Min HK; Park SN; Hong SH
    J Microbiol; 2006 Feb; 44(1):72-6. PubMed ID: 16554720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma.
    Müller-Breitkreutz K; Mohr H
    J Med Virol; 1998 Nov; 56(3):239-45. PubMed ID: 9783692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.